These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 11741302

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, Hatano T, Ogawa Y, Ochiai A.
    Prostate; 2006 Nov 01; 66(15):1573-84. PubMed ID: 16927388
    [Abstract] [Full Text] [Related]

  • 4. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M.
    Prostate; 2009 Aug 01; 69(11):1222-34. PubMed ID: 19434660
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H, Horiguchi Y, Ohno Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M.
    Prostate; 2007 Jun 01; 67(8):840-8. PubMed ID: 17394194
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM.
    Clin Cancer Res; 2003 Jul 01; 9(7):2587-97. PubMed ID: 12855635
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
    Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A.
    Cancer Res; 2001 Mar 01; 61(5):2177-82. PubMed ID: 11280783
    [Abstract] [Full Text] [Related]

  • 11. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
    Yonou H, Ochiai A, Goya M, Kanomata N, Hokama S, Morozumi M, Sugaya K, Hatano T, Ogawa Y.
    Prostate; 2004 Mar 01; 58(4):406-13. PubMed ID: 14968441
    [Abstract] [Full Text] [Related]

  • 12. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET.
    Cancer Res; 2005 Dec 01; 65(23):10921-9. PubMed ID: 16322239
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 01; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
    Downing S, Bumak C, Nixdorf S, Ow K, Russell P, Jackson P.
    Mol Carcinog; 2003 Nov 01; 38(3):130-40. PubMed ID: 14587098
    [Abstract] [Full Text] [Related]

  • 17. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo.
    Rubin J, Fan X, Rahnert J, Sen B, Hsieh CL, Murphy TC, Nanes MS, Horton LG, Beamer WG, Rosen CJ.
    Prostate; 2006 Jun 01; 66(8):789-800. PubMed ID: 16482567
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
    Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin GV, Shurin MR.
    J Urol; 2003 Nov 01; 170(5):2026-30. PubMed ID: 14532846
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.